Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01178 (
oxytocin
)
15,767
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Vasopressin receptors in distal segments of the rat nephron were identified in isolated tubules using two labeled ligands: the [1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid), 2-(O-methyl)tyrosine,4-
threonine
,8-ornithine,9-125I-tyrosylamide]- vasotocin [125I-d(CH2)5[Tyr(Me)2,Thr4,Tyr-NH2(9)]OVT] and the linear analogue, Phaa1,D-Tyr(Me)2,Phe3,Gln4,Asn5,Arg6, Pro7,Arg8,125I-Tyr-NH2(9) [125I-Tyr-NH2(9)-linear antagonist (LA)-V1a)]. Specific 125I-d(CH2)5[Tyr(Me)2,Thr4,Tyr-NH2(9)]-OVT binding to cortical collecting ducts (CCD) was saturable with incubation time and dose, reversible after elimination of free ligand, and characterized by the following rank order for recognition of vasopressin analogues: desGly9-d-(CH2)5-[Tyr(Et)2,Val4]arginine vasopressin (AVP) greater than or equal to d(CH2)5[Tyr-(ET)2,Val4]AVP greater than or equal to AVP greater than or equal to d(CH2)5[Tyr(Me)2]AVP = 1-desamino-8-D-arginine vasopressin (DDAVP) greater than or equal to Tyr-NH2(9)-LA-V1a greater than [8-arginine]vasotocin (AVT) greater than d(CH2)5[Tyr(Me)2, Thr4,Tyr-NH2(9)]OVT greater than
oxytocin
(OT) greater than [Phe2,Orn8]VT much greater than [Thr4,Gly7]-OT. Scatchard plots of dose-dependent 125I-Tyr-NH2(9)-LA-V1a binding to medullary thick ascending limbs (MTAL), CCD, and outer medullary collecting ducts (OMCD) revealed the presence of high- and low-affinity binding sites corresponding to V1a and V2 vasopressin receptors, respectively; the densities of V1a receptors are approximately 20% of the total number of vasopressin receptors in CCD and 5% in MTAL and OMCD.
...
PMID:Pharmacological characterization of V1a vasopressin receptors in the rat cortical collecting duct. 153 99
To identify and characterize
oxytocin
receptors, a 125I-labeled photoreactive
oxytocin
antagonist was synthesized. The specific
oxytocin
antagonist [1-(beta-mercapto-beta,beta- cyclopentamethylenepropionic acid), 2-O-methyltyrosine,4-
threonine
,8- ornithine,9-tyrosylamide]
oxytocin
([Mca,Tyr(O-Me)2,Thr4,Orn8,Tyr9-NH2]
oxytocin
) described by Elands et al. (Elands, J., Barberis, C., Jard, S., Tribollet, E., Dreifuss, J.-J., Bankowski, K., Manning, M., and Sawyer, W. H. (1987) Eur. J. Pharmacol. 147, 192-207) bound to the guinea pig uterine oxytocin receptor with high affinity (apparent Kd = 0.74 nM). The introduction of a 4-azidophenylamidino group at Orn8 resulted in the photoreactive ligand [Mca1,Tyr(O-Me)2,Thr4,Orn(4-azidophenylamidino)8,Tyr9- NH2]
oxytocin
, which retained the high binding affinity (Kd = 0.69 nM) of the parent compound. The photoreactive antagonist monoiodinated at Tyr9 had approximately double (Kd = 0.39 nM) the affinity of the photoreactive antagonist and several times that of
oxytocin
(Kd = 2.6 nM) for the guinea pig uterine oxytocin receptor. In photo-affinity labeling experiments using myometrial membranes obtained from guinea pigs during late pregnancy, the 125I-labeled photoreactive antagonist specifically labeled a protein with an apparent molecular mass of between 68 and 80 kDa: the labeling of this protein was completely suppressed by a 100-fold molar excess of
oxytocin
and oxytocin receptor-specific agonists, but not by vasopressin analogues specific for V1 or V2 receptors or by other peptide hormones. The ability of
oxytocin
to suppress labeling was decreased in the presence of guanosine 5'-O-(thiotriphosphate) or in the absence of Mn2+. Digestion of the photolabeled oxytocin receptor with endoglycosidase F gave rise to a protein with an apparent molecular mass of 38 +/- 2 kDa. The endoglycosidase F effect and the lack of endoglycosidase H action show that the myometrial oxytocin receptor is highly glycosylated with asparagine-linked complex oligosaccharide chains. Our results suggest that the radioiodinated photoreactive
oxytocin
antagonist could be a helpful tool in the isolation and further characterization of the oxytocin receptor.
...
PMID:Identification and enzymatic deglycosylation of the myometrial oxytocin receptor using a radioiodinated photoreactive antagonist. 165 65
The effect of a recently developed
oxytocin
antagonist dTVT, i.e. deamino-[2-D-tyrosine(OEt)-4-
threonine
-8-ornithine]
oxytocin
on uterine contraction of pregnant rats was studied in vitro. The following results were obtained. 1. dTVT treatment did not affect spontaneous PGE2- or PGF2 alpha-stimulated contraction, while it slightly suppressed PGE1 analogue (Gemeprost)-stimulated contraction of the uterus. 2. Following treatment with dTVT (5-50 micrograms/ml),
oxytocin
-stimulated uterine contraction was gradually and slowly suppressed, resulting in an attenuation curve. Ritodrine treatment, on the other hand, rapidly suppressed spontaneous uterine contraction as well as contraction stimulated by various oxytocics. Suppression of
oxytocin
-stimulated uterine contraction by dTVT took much longer (14.8 +/- 1.1 min) to take effect than that by ritodrine (less than 1 min).
...
PMID:Effects of oxytocin antagonist (dTVT) and ritodrine on spontaneous and oxytocics-induced uterine contractions in pregnant rats. 195 39
Two selective radioligands for
oxytocin
receptors, [3H]-[4-
threonine
,7-glycine]
oxytocin
[( 3H]-[Thr4,Gly7]OT) and 125I-[1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid), 2-(O-methyl)tyrosine, 4-
threonine
, 8-ornithine, 9-tyrosine amide]-
oxytocin
(125I-OTA), were used to characterize
oxytocin
receptors from two pig kidney-derived cell lines, LLC-PK1 and LLC-PK1L. [3H]-[Thr4,Gly7]OT and 125I-OTA bind with high affinity (mean Kd values of 14 and 0.06 nM, respectively) to the same population of sites on LLC-PK1 cell membranes [maximum binding (Bmax) of 100 fmol/mg membrane protein]. These sites had the expected ligand selectivity of
oxytocin
receptors. [3H]-[Thr4,Gly7]OT and 125I-OTA binding sites could be distinguished from V2 vasopressin receptors present on LLC-PK1 and LLC-PK1L cells on the basis of clearly different maximal capacities and ligand selectivities, different sensitivities to insulin and serum, and absence of heterologous downregulation.
Oxytocin
receptors from LLC-PK1 cells have no functional relationship with adenylate cyclase. [Thr4,Gly7]OT affected neither the basal adenosine 3',5'-cyclic monophosphate (cAMP) content nor the vasopressin-induced cAMP accumulation by LLC-PK1 cells. Xenopus laevis oocytes injected with LLC-PK1 cell mRNA responded to [Thr4,Gly7]OT by an increase in 45Ca2+ outflux; this effect is antagonized by a highly selective
oxytocin
antagonist.
...
PMID:Oxytocin receptors from LLC-PK1 cells: expression in Xenopus oocytes. 215 46
To investigate whether a putative
oxytocin
(OT) receptor blocker 1-deamino-[2-D-tyrosine (OEt)-4
threonine
-8-ornithine]
oxytocin
(dTVT) inhibits OT binding to its receptors, we studied binding of [3H]OT to late-pregnant human, guinea pig, and rat myometrial and decidual membranes and competition of dTVT with this binding. Decidua as well as myometrium of all three species bound [3H]OT with high affinity (Kd 1-3 nM) and limited capacity. The concentration of binding sites in decidual membranes was slightly lower than in myometrial membranes in human and guinea pig uterus and twice that of myometrial membranes in day 20 pregnant rat uterus. dTVT competed with [3H]OT with highest affinity in guinea pig myomterium and decidua, the potency ratios ([dTVT]50: [OT]50) being 1.9 and 3.3, respectively. The potency ratios in rat uterine tissues and human decidua were slightly higher (4 to 5) and highest in human myometrium, 23.3. Excess dTVT completely inhibited [3H]OT binding in all six tissues, indicating binding to the same receptor sites. Because of the high-affinity binding of dTVT to
oxytocin
receptors in human decidua and myometrium, this
oxytocin
analogue may be a very effective tocolytic agent in the treatment of threatened preterm labor.
...
PMID:Oxytocin antagonist (dTVT) and oxytocin receptors in myometrium and decidua. 254 Jul 61
Saturation analysis and competition experiments were performed to identify and characterize [3H]arginine vasopressin binding to human myometrium and decidua in late pregnancy. [3H]Arginine vasopressin bound with affinity similar to that of [3H]
oxytocin
to both tissues (dissociation constant 1 to 2 nmol/L). The concentration of [3H]arginine vasopressin binding sites was high, particularly in decidua, but in all instances was about 50% to 60% of [3H]
oxytocin
binding. Analogs with selective oxytocic potency (4-
threonine
oxytocin
, isotocin) had high affinity to both [3H]arginine vasopressin and [3H]
oxytocin
binding sites, as did analogs with both oxytocic and vasopressor activity (vasotocin). Analogs with selective antidiuretic activity (1-deamino-8-D-arginine vasopressin) showed drastically reduced affinity to [3H]
oxytocin
binding sites and relatively low but significantly higher affinity to [3H]arginine vasopressin binding sites. A new
oxytocin
antagonist (RW22164 or [1-deamino-2D-tyrosine-(O-ethyl)-4-
threonine
-8-ornithine]
oxytocin
) competitively bound to both binding sites. Its affinity to [3H]
oxytocin
binding sites was greater than to [3H]arginine vasopressin binding sites whereas the relative affinities of a predominantly vasopressor antagonist [Manning compound) were reversed, suggesting the presence of distinct receptors for
oxytocin
and arginine vasopressin in pregnant human myometrium and decidua.
...
PMID:Vasopressin receptors in human pregnant myometrium and decidua: interactions with oxytocin and vasopressin agonists and antagonists. 255 63
An oxytocic antagonist, [1-(beta-mercapto-beta, beta-cyclopentamethylenepropionic acid,2-O-methyltyrosine,4-
threonine
, 8-ornithine,9-tyrosylamide]vasotocin (d(CH2)5[Tyr(Me)2, Thr4,Tyr-NH2(9)]OVT [corrected], was monoiodinated at the phenyl moiety of the tyrosylamide residue at position 9. 125I-labelling was performed with 1,3,4,6-tetrachloro-3 alpha,6 alpha-diphenyl-glycoluril. Iodination resulted in an increased affinity for rat uterine
oxytocin
receptors. A considerably lower affinity for rat vascular V1- and renal V2-receptors was found, resulting in a highly specific oxytocin receptor ligand. 125I-labelled d(CH2)5[Tyr(Me)2,Thr4,Tyr-NH2(9)]OVT [corrected] was demonstrated to bind selectively to one population of binding sites in rat uterus and ventral hippocampal membrane preparations. Dissociation constants ranged between 0.03 and 0.06 nM. After 3 days of exposure autoradiography revealed binding in regions known to contain
oxytocin
receptors as well as labelling in some new regions, while no binding was found in the lateral septum, a structure containing mainly [8-arginine]vasopressin receptors. The high specific radioactivity of 125I-labelling allowed important reductions in membrane protein amount, gain in precision of binding analysis as well as considerably lower exposure times for autoradiography.
...
PMID:125I-labelled d(CH2)5[Tyr(Me)2,Thr4,Tyr-NH2(9)]OVT: a selective oxytocin receptor ligand. 283 49
[4-(0-methyl)-L-threonine]-
oxytocin
, a new analogue of neurohypophyseal hormone
oxytocin
, was synthesized. Its uretonic activity was found to be 150 I. U./mg. The comparison of the potency of [4-(0-methyl)-
threonine
]-
oxytocin
with a very active analogue [4-
threonine
]-
oxytocin
and low active analogue [4-isoleucine] -
oxytocin
supports the hypothesis of high uterotonic activity of 4-substituted analogue of
oxytocin
to be related to the presence of suitably located hydrophilic and lipophilic grouper in the side chain in position 4, and to the proton donor/proton acceptor properties of hydrophilic group.
...
PMID:[4-(0-methyl)-L-threonine] -oxytocin. Synthesis and uterotonic activity. 285 67
A new, highly selective radio-iodinated oxytocin receptor antagonist [( 1-(beta-mercapto-beta, beta-cyclopentamethylenepropionic acid, 2-O-methyltyrosine, 4-
threonine
, 8-ornithine, 9-tyrosylamide]-vasotocin) was used to identify and quantitate specific binding sites for the neurohypophyseal hormone
oxytocin
with in vitro incubation of rat brain sections and autoradiography. Exclusively
oxytocin
binding sites were detected in view of the high affinity of the [125I]-labelled
oxytocin
antagonist for
oxytocin
binding sites and the negligible affinity for the vasopressin liver (V1) and kidney (V2) receptor types. The putative
oxytocin
receptors were abundantly present in several brain regions, where previously discrimination between
oxytocin
and vasopressin binding was difficult, i.e. the olfactory nucleus, the islands of Calleja, the ventromedial nucleus of the hypothalamus, the central amygdaloid nucleus and the ventral subiculum of the hippocampus. In addition
oxytocin
receptors were demonstrated in other areas, such as the taenia tecta, dorsolateral caudate putamen, ventral pallidum, accumbens, lateral septum, bed nucleus of the stria terminalis, thalamic paraventricular nucleus, lateral, basolateral and medial amygdala, the dorsal subiculum, perirhinal cortex and the amygdaloid-hippocampal area. The high affinity and the low detection threshold of this [125I]-labelled
oxytocin
antagonist permitted identification of
oxytocin
receptors in new regions such as the ventral part of the lateral septum, medial septum, dorsal motor nucleus of the vagus nerve and the olive nuclei in the brain stem.
...
PMID:Topography of the oxytocin receptor system in rat brain: an autoradiographical study with a selective radioiodinated oxytocin antagonist. 285 12
The substitution of glutamine by
threonine
in position 4 of
oxytocin
, deamino-
oxytocin
, deamino-1-carba-
oxytocin
, and deamino-6-carba-
oxytocin
was found to increase the elimination rate of all analogs examined from the uterine receptor compartment in rat. However, this substitution was without any effect on the time course of uterotonic response in the case of vasotocin and deamino-vasotocin. These results suggest that the topological relationships of the 4 and 8 positions may show an important effect on elimination rate of
oxytocin
and vasotocin analogs from the rat uterine compartment.
...
PMID:Effect of threonine in position 4 in oxytocin and vasotocin analogs on the time course of uterotonic response. 311 17
<< Previous
1
2
3
4
Next >>